Repository logo
Communities & Collections
All of DSpace
  • English
  • العربية
  • বাংলা
  • Català
  • Čeština
  • Deutsch
  • Ελληνικά
  • Español
  • Suomi
  • Français
  • Gàidhlig
  • हिंदी
  • Magyar
  • Italiano
  • Қазақ
  • Latviešu
  • Nederlands
  • Polski
  • Português
  • Português do Brasil
  • Srpski (lat)
  • Српски
  • Svenska
  • Türkçe
  • Yкраї́нська
  • Tiếng Việt
Log In
New user? Click here to register.Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Kamal, A.T.M. Mostafa"

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • Results Per Page
  • Sort Options
  • No Thumbnail Available
    Item
    A review of β-caryophyllene oxide for its pharmacological properties supported by in silico findings
    (International Islamic University Chittagong, 2022-12) Kamal, A.T.M. Mostafa
    Bicyclic sesquiterpene, β-caryophyllene oxide (BCO) is one of the major components of essential oil derived from aromatic plants. It is reported to possess several interesting pharmacological prospects. BCO’s ability to suppress a few signaling cascades and down regulating various gene products responsible for cancer development against several cancer cell lines was seen along with some analgesic properties. Besides, its interaction with enzymes responsible for metabolism of the drugs performed in-vitro and in-vivo was found to show diminishing and enhancing effects on the enzymes. All the possible relevant published articles on BCO were collected using some popular search engines such as Google Scholar, Pubmed, ScienceDirect etc. The molecular docking was carried out with the help of Schrodinger Suites-Maestro 2017-1. In addition, the in-silico findings also provided strong evidence in favor of BCO with the ability to be a prospective therapeutic agent. However, from all the information gathered on this compound and clinical trials, this compound may yield beneficial results novel drug discovery.

DSpace software copyright © 2002-2025 LYRASIS

  • Privacy policy
  • End User Agreement
  • Send Feedback